Claims
- 1-36. (Canceled)
- 37. A method of suppressing a symptom of an allergic response in a subject, the method comprising: administering to the subject a first dose of an immunostimulatory nucleic acid; and administering to the subject a second dose of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence comprising 5′-CG-3′, and wherein the second dose is administered from about 1 day to about 8 weeks after the first dose.
- 38. The method of claim 37, wherein the second dose is administered from about 1 day to about 7 days after the first dose.
- 39. The method of claim 37, wherein the second dose is administered from about 1 week to about 2 weeks after the first dose.
- 40. The method of claim 37, wherein the second dose is administered from about 2 weeks to about 4 weeks after the first dose.
- 41. The method of claim 37, wherein the first dose is co-administered with an antigen.
- 42. The method of claim 37, wherein the second dose is co-administered with an antigen.
- 43. The method of claim 37, wherein the first dose and second dose are co-administered with an antigen.
- 44. The method of claim 37, wherein the subject is a human.
- 45. The method of claim 37, wherein the first and the second doses are administered by inhalation.
- 46. A method for maintaining suppression of a Th2 immune response in a subject, the method comprising: administering to a subject a first dose of an immunostimulatory nucleic acid; and administering to the subject a second dose of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence comprising 5′-CG-3′, and wherein the second dose is administered from about 1 day to about 8 weeks after the first dose.
- 47. The method of claim 46, wherein the second dose is administered from about 1 day to about 7 days after the first dose.
- 48. The method of claim 46, wherein the second dose is administered from about 1 week to about 2 weeks after the first dose.
- 49. The method of claim 46, wherein the second dose is administered from about 2 weeks to about 4 weeks after the first dose.
- 50. The method of claim 46, wherein the subject is a human.
- 51. The method of claim 46, wherein the first and the second doses are administered by inhalation.
- 52. A method for maintaining stimulation of a Th1 immune response in a subject, the method comprising: administering to a subject a first dose of an immunostimulatory nucleic acid; and administering to the subject a second dose of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence comprising 5′-CG-3′, and wherein the second dose is administered from about 1 day to about 8 weeks after the first dose.
- 53. The method of claim 52, wherein the second dose is administered from about 1 day to about 7 days after the first dose.
- 54. The method of claim 52, wherein the second dose is administered from about 1 week to about 2 weeks after the first dose.
- 55. The method of claim 52, wherein the second dose is administered from about 2 weeks to about 4 weeks after the first dose.
- 56. The method of claim 52, wherein the subject is a human.
PRIORITY OF THE INVENTION
[0001] This application claims priority under Title 35 § 119(e), of U.S. Provisional Application No. 60/179,991, filed Feb. 3, 2000, entitled IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE TREATMENT OF ASTHMA AND ALLERGY, the entire contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60179991 |
Feb 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09776479 |
Feb 2001 |
US |
Child |
10831778 |
Apr 2004 |
US |